What Johnson & Johnson's Earnings Mean For Mutual Fund Investors (JNJ)

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed income news, reports, video and more.

Municipal bonds news, reports, video and more.

Practice management news, reports, video and more.

Portfolio management news, reports, video and more.

Retirement news, reports, video and more.

Learn from industry thought leaders and expert market participants.

Deepen your understanding of Responsible Investing and learn how it can potentially help you build a more successful practice.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

What Johnson & Johnson's Earnings Mean For Mutual Fund Investors (JNJ)

Johnson & Johnson logo
Before the opening bell on Tuesday, Johnson & Johnson (JNJ) released its first quarter financial results. Here’s what the results mean for mutual fund investors.

Inside JNJ’s Results

Earnings

The company reported earnings of $4.32 billion, or $1.53 per share, down from $4.73 billion, or $1.64 per share, last year. Excluding special items, earnings were $1.56 per share – above analysts’ view of $1.54.

Revenue
Revenue declined 4.1% to $17.37 billion from $18.12 billion last year. Analysts expected to see revenue of $17.31 billion.

Outlook
Looking ahead, JNJ now expects to see FY2015 EPS between $6.04 and $6.19. Previously, the company expected to see EPS between $6.12 and $6.27 per share. Analysts expect to see EPS of $6.16.

JNJ To Seek Acquisitions

The company has a large cash stockpile which it may plan to use for future acquisitions to grow more profitable businesses. Last month, JNJ failed to acquire Pharmacyclics, but there could be more deals in the pipeline.

Mutual Funds to Watch

Investors interested in JNJ may be interested in the funds listed below. These funds currently have the largest stakes in the company.

The Bottom Line

The funds listed above allow investors to gain exposure to JNJ while remaining diversified. Investors interested in JNJ may also be interested in Pfizer (PFE) and Merck (MRK).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.


Read Next

Johnson & Johnson logo

What Johnson & Johnson's Earnings Mean For Mutual Fund Investors (JNJ)

Before the opening bell on Tuesday, Johnson & Johnson (JNJ) released its first quarter financial results. Here’s what the results mean for mutual fund investors.

Inside JNJ’s Results

Earnings

The company reported earnings of $4.32 billion, or $1.53 per share, down from $4.73 billion, or $1.64 per share, last year. Excluding special items, earnings were $1.56 per share – above analysts’ view of $1.54.

Revenue
Revenue declined 4.1% to $17.37 billion from $18.12 billion last year. Analysts expected to see revenue of $17.31 billion.

Outlook
Looking ahead, JNJ now expects to see FY2015 EPS between $6.04 and $6.19. Previously, the company expected to see EPS between $6.12 and $6.27 per share. Analysts expect to see EPS of $6.16.

JNJ To Seek Acquisitions

The company has a large cash stockpile which it may plan to use for future acquisitions to grow more profitable businesses. Last month, JNJ failed to acquire Pharmacyclics, but there could be more deals in the pipeline.

Mutual Funds to Watch

Investors interested in JNJ may be interested in the funds listed below. These funds currently have the largest stakes in the company.

The Bottom Line

The funds listed above allow investors to gain exposure to JNJ while remaining diversified. Investors interested in JNJ may also be interested in Pfizer (PFE) and Merck (MRK).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.


Read Next